Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG ZEST
- Development stage
- Unknown
- Lead developer
- ADDUCO RBS
- Administration
- Oral
01
Overview
MG ZEST is a nutraceutical supplement developed by ADDUCO RBS, specifically formulated to address magnesium deficiency. It is marketed in tablet form, including variants such as MG ZEST 30 and MG ZEST 60. The product functions by providing an exogenous source of magnesium, an essential mineral required for over 300 enzymatic reactions in the human body, including those involved in protein synthesis, muscle and nerve function, blood glucose control, and blood pressure regulation. As a nutraceutical, it is intended to restore and maintain healthy magnesium levels in individuals experiencing deficiency.
- Brand names
- MG ZESTMG ZEST 60MG ZEST 30 Tab
Beyond the preview
Go deeper on MG ZEST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG ZEST.